Inotersen
 | |
| Clinical data | |
|---|---|
| Trade names | Tegsedi |
| Other names | GSK-2998728, ISIS-420915 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Subcutaneous |
| Drug class | Antisense oligonucleotides |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C230H318N69O121P19S19 |
| Molar mass | 7183.08 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Inotersen, sold under the brand name Tegsedi, is a 2'-O-(2-methoxyethyl) (2'-MOE) antisense oligonucleotide medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis.[6][7] The sequence is TCTTG GTTACATGAA ATCCC, where C is methylated C, and the first and third section (bases 1-5 and 16–20, separated from the middle section by spaces) are MOE-modified.[8]
The most common side effects are injection site reactions (redness, swelling, bleeding, pain, rash, and itching at the injection site), nausea, headache, tiredness, low platelet counts, and fever.[6]
Inotersen can cause serious side effects, including low platelet counts and kidney inflammation.[6] Because of these serious side effects, Inotersen is available in the United States only through a restricted program called the Tegsedi Risk Evaluation and Mitigation (REMS) Program.[6]
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[9]
History
[edit]Inotersen was approved for medical use in the European Union in July 2018.[5]
The US Food and Drug Administration (FDA) approved inotersen in October 2018.[6] The application for inotersen was granted orphan drug designation.[10]
The FDA approved inotersen based on evidence from one clinical trial (Trial 1/NCT01737398) that included 172 participants with hereditary transthyretin-mediated amyloidosis.[6] The trial was conducted at 24 sites in Australia, Europe, South America, and the United States.[6] The benefits and side effects of inotersen were evaluated in one clinical trial that enrolled participants with hereditary transthyretin-mediated amyloidosis.[6] Participants were randomly assigned to receive inotersen or placebo by subcutaneous injection given once a week for 65 weeks.[6] During the first week of treatment, participants received three doses of treatment, followed by once weekly subcutaneous injections for 64 weeks.[6] Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed.[6]
References
[edit]- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Tegsedi inotersen injection" (PDF). Product Monograph Including Patient Medication Information. Akcea Therapeutics, Inc. Archived (PDF) from the original on 1 June 2022. Retrieved 1 June 2022 – via The Drug and Health Product Register, Government of Canada.
- ^ "Tegsedi 284 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 15 October 2019. Archived from the original on 7 October 2020. Retrieved 3 October 2020.
- ^ "Tegsedi- inotersen injection, solution". DailyMed. 2 September 2020. Archived from the original on 7 October 2020. Retrieved 3 October 2020.
- ^ a b "Tegsedi EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 8 October 2020. Retrieved 3 October 2020.
- ^ a b c d e f g h i j k "Drug Trial Snapshot: Tegsedi". U.S. Food and Drug Administration (FDA). 23 July 2019. Archived from the original on 19 December 2019. Retrieved 18 December 2019.
This article incorporates text from this source, which is in the public domain.
- ^ Benson MD, Dasgupta NR, Monia BP (February 2019). "Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis". Neurodegenerative Disease Management. 9 (1): 25–30. doi:10.2217/nmt-2018-0037. PMID 30561247. S2CID 56178847.
- ^ Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, et al. (June 2020). "Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis". Nucleic Acid Therapeutics. 30 (3): 153–163. doi:10.1089/nat.2019.0822. PMC 7249474. PMID 32286934.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original on 17 September 2020. Retrieved 16 September 2020.
- ^ "Inotersen Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 July 2012. Archived from the original on 19 December 2019. Retrieved 18 December 2019. This article incorporates text from this source, which is in the public domain.
